Results 11 to 20 of about 4,279 (197)
Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center
Antibiotics, 2021 Dalbavancin is a lipoglycopeptide approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The aim of the study was to evaluate the efficacy and safety in all patients who received at least one administration of ...
Lucia Brescini +16 more
doaj +1 more source
Antibiotics, 2022 The antibiotic dalbavancin is approved for intravenous treatment of adults with acute bacterial skin and skin structure infections. This study aimed to observe the use, effectiveness, and safety of dalbavancin in clinical practice in Germany.
Frank Hanses +4 more
doaj +1 more source
Hospital Pharmacy, 2014 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Dennis J, Cada +2 more
openaire +2 more sources
Ototoxicity associated with extended dalbavancin treatment for a shoulder prosthetic joint infection
BMC Infectious Diseases, 2023 Background Dalbavancin is a lipoglycopeptide antibiotic approved for treatment of skin and soft tissue infections, administered as a single or two-dose treatment.
Anna Lange +2 more
doaj +1 more source
Journal of Global Antimicrobial Resistance, 2022 : Objective: To evaluate the cost-effectiveness of dalbavancin compared with standard of care (SoC) treatment as daptomycin or teicoplanin in patients with sternal wound infections (SWI).
Renato Pascale +12 more
doaj +1 more source
Antimicrobial Activity of the Quinoline Derivative HT61 against Staphylococcus aureus Biofilms. [PDF]
, 2020 Staphylococcus aureus biofilms are a significant problem in health care settings, partly due to the presence of a nondividing, antibiotic-tolerant subpopulation. Here we evaluated treatment of S.
Allan, RN +7 more
core +2 more sources
In Vitro Efficacy of Dalbavancin as a Long-Acting Anti-Biofilm Agent Loaded in Bone Cement
Antibiotics, 2023 Based on previous studies by our group in which we demonstrated that dalbavancin loaded in bone cement had good elution capacity for the treatment of biofilm-related periprosthetic infections, we now assess the anti-biofilm activity of dalbavancin and ...
Mar Sánchez-Somolinos +7 more
doaj +1 more source
Dalbavancin is thermally stable at clinically relevant temperatures against methicillin-sensitive Staphylococcus Aureus [PDF]
Journal of Bone and Joint Infection, 2023 Introduction: While the rate of orthopaedic infections has remained constant over the years, the burden on healthcare systems continues to rise with an aging population.
A. K. Hoyt +7 more
doaj +1 more source
, 2017 Since 2010 the new antimicrobials introduced have activity against resistant Gram negative bacteria, long half-lives against Gram positive bacteria, better activity against Clostridium difficile, and safer antifungal properties. Limiting factors to using
Roland, Will
core +1 more source
Studies on Staphylococcus aureus Isolated from Pimples [PDF]
, 2017 Background and Objective: Pimples (acne) are small skin lesions or inflammations of the skin. The most common factor causing acne is the hormonal changes that occur during adolescent and teenage years.
Ajayi, A. A. +3 more
core +6 more sources